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Two alternatively-spliced human 
nebulin isoforms with either 
exon 143 or exon 144 and their 
developmental regulation
Le Thanh Lam1, Ian Holt1,2, Jenni Laitila3, Mubashir Hanif3, Katarina Pelin4, Carina Wallgren-
Pettersson3, Caroline A. Sewry1,5 & Glenn E. Morris1,2
Nebulin is a very large protein required for assembly of the contractile machinery in muscle. Mutations 
in the nebulin gene NEB are a common cause of nemaline myopathy. Nebulin mRNA is alternatively-
spliced so that each mRNA contains either exon 143 or exon 144. We have produced monoclonal 
antibodies specific for the regions of nebulin encoded by these two exons, enabling analysis of 
expression of isoforms at the protein level for the first time. All antibodies recognized a protein of the 
expected size (600–900 kD) and stained cross-striations of sarcomeres in muscle sections. Expression of 
exon 143 is developmentally-regulated since newly-formed myotubes in cell culture expressed nebulin 
with exon 144 only; this was confirmed at the mRNA level by qPCR. In fetal muscle, nebulin with 
exon 143 was expressed in some myotubes by 12-weeks of gestation and strongly-expressed in most 
myotubes by 17-weeks. In mature human muscle, the exon 144 antibody stained all fibres, but the exon 
143 antibody staining varied from very strong in some fibres to almost-undetectable in other fibres. 
The results show that nebulin containing exon 144 is the default isoform early in myogenesis, while 
regulated expression of nebulin containing exon 143 occurs at later stages of muscle development.
Nebulin is a large protein expressed mainly in the skeletal muscle sarcomere1–3. It has a modular structure, with 
more than 200 simple repeats, each binding to actin along the length of the thin filament1,2. The most impor-
tant roles of nebulin are to act as a thin filament stabiliser and in defining Z-disc width4–7. Although all known 
exons in the NEB gene could theoretically encode a protein of 8,525 amino-acids8, numerous alternative splic-
ing events typically result in smaller proteins in the range 600–900 kD9,10. Whereas most of these alternative 
splicing events simply remove exons from the nebulin mRNAs, all nebulin mRNAs contain either exon 143 or 
exon 144 but never both2. In the central region of nebulin, the 200+ simple repeats are further organised into 
26 different super-repeats. The mutually exclusive exons 143 and 144 are found in S21 and define S21a and S21b 
respectively1,2.
The amino-acid sequence of nebulin is highly conserved among species. The sequence encoded by exon 143 
shows complete homology between mouse, rat, and human. However, S21a and S21b differ in charge and hydro-
phobicity2, suggesting different functional roles for the alternative isoforms. The S21 super-repeat is just outside 
the Z-disc anchorage region. It contains the binding site for KLHL40, a muscle-specific Kelch protein that also 
binds leiomodin-3 (LMOD3) and stabilizes thin filament assembly3,11. Mutations in several proteins, including 
nebulin, KLHL4011 and LMOD312, can cause nemaline myopathy, a congenital disorder of muscle characterized 
by the presence of nemaline bodies, which are aggregates of thin filament proteins13,14. Mutations in two other 
Kelch genes, those for KLHL41 and KBTBD13, also cause forms of nemaline myopathy15.
We have produced eleven monoclonal antibodies for the S21 region, including three that are specific for nebu-
lin protein encoded by exon 143 or exon 144. For the first time, these new antibodies have enabled a study of the 
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two nebulin isoforms during human muscle development at the protein level. Immunolocalization has enabled us 
to follow nebulin isoform expression in different cell and fibre types at several stages of human muscle develop-
ment, from early myogenesis in cell culture, through fetal stages, to mature skeletal muscle. We suggest that S21a 
(nebulin with exon 143) has functions that are required at later stages of muscle development.
Results
New monoclonal antibodies confirm the existence of nebulin isoforms at the protein level. 
BALB/c mice were immunised with recombinant fragments of nebulin encoded by exons 138–143 or 138-
(143)144. The fragments were produced from pET plasmids as fusion proteins with thioredoxin. The use of frag-
ments larger than exons 143 or 144 alone was employed to increase their immunogenicity, since the amino-acid 
sequence of exon 143 is identical in man and mouse.
Our initial hybridoma screening was based on ELISA with the two fragments, with the aim of selecting mAbs 
that recognised 138–143, but not 138–144, and vice-versa. The first attempt produced only mAbs that were 
directed against exons 138–142 common to both fragments (Table 1A).
It was possible to map the epitopes recognised by 3 of these mAbs using phage-displayed peptide libraries and 
they were binding to regions encoded by exon 140 (Fig. 1). Other mAbs did not select peptides from the library 
and could not be mapped in this way. This panel of 6 mAbs all recognised a band on western blots of human mus-
cle consistent with the expected size of nebulin (>427 kD dystrophin) (Fig. 2A) and stained sarcomeric bands 
in longitudinal skeletal muscle sections (Fig. 3A). To produce the desired exon 143/144 mAbs, we screened with 
new fusion proteins expressing exon 143 only or exon 144 only and produced two mAbs specific for exon 143 
(NEB-3F4 and NEB-6E6) and one mAb specific for exon 144 (NEB-9H1) (Table 1B). The two exon 143 mAbs 
stained sarcomeric cross-striations in only a subset of fibres and with variable intensity, whereas the exon 144 
mAb stained the striations in all fibres with little variation in intensity (Fig. 3B). All three mAbs stained a similar 
nebulin band on western blots of normal adult human muscle (Fig. 2B). Lower Mr bands on the blot are likely 
degradation products of nebulin. Figure 2C shows that the largest nebulin band is similar in size to nesprin-2 
(792 kD) or slightly smaller. We have labelled it “800 kD” as an approximation, since it is clearly smaller than the 
predicted “unspliced” size (980 kD) of the largest, full-length nebulin sequence8, as expected9,10.
Early myotubes in cell culture have only nebulin with exon 144, but myotubes in fetal muscle at 12 
weeks of gestation also express nebulin with exon 143. Cultures of human myotubes from immortal-
ised clonal cell lines were examined 4 days after induction of myoblast fusion by removal of serum from the culture 
medium. At this stage, over 60% of nuclei are within multinucleate myotubes, levels of muscle-specific creatine kinase 
Antibody Epitope (encoding exons) Sub-type
(A)
NEB-6B5 ex140 IgG1
NEB-9C4 ex140 IgG1
NEB-8D2 ex140 IgG1
NEB-9A11 ex138-142 IgG1
NEB-10A7 ex138-142 IgG1
NEB-9D9 ex138-142 IgG1
NEB-8G3 ex138-142 IgG1
NEB-7D5 ex138-142 IgG1
(B)
NEB-3F4 ex143 IgG1
NEB-6E6 ex143 IgG1
NEB-9H1 ex144 IgG1
Table 1. New monoclonal antibodies against human nebulin.
Figure 1. Phage display epitope mapping of three nebulin mAbs. Biopanning with a mixture of the 11 mAbs 
succeeded in selecting from the library, 2 phage-displayed peptides recognized by 3 of the mAbs. The peptide 
sequences obtained by sequencing the phage DNA inserts are aligned with the protein sequence encoded by 
nebulin exons 138-139-140-141-142-144 and they show an excellent match of 6 or 7 amino-acids within each of 
the two overlapping 15-mer peptides. Peptide PEP3 was recognized by both NEB-6B5 and NEB-9C4, whereas 
PEP6 was recognized by both NEB-9C4 and NEB-8D2. Both peptides are encoded by exon 140 of the NEB gene.
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(M-CK) are high and myosins (fast, slow and neonatal) are already present (data not shown). Nebulin was barely 
detectable with exon 143 mAbs, but the exon 144 and exon 140 mAb showed a uniform staining of the myotube 
cytoplasm (Fig. 4). The same result was obtained with two different cell lines, from donors aged 5 days or 53 years.
qPCR confirmed that only 1% of nebulin mRNAs in myotube cultures had exon 143, whereas in adult mus-
cle up to two-thirds of the mRNA had exon 143 (Table 2). Levels of nebulin mRNA containing exon 143 are 
much higher in fetal muscle, and higher again in adult muscle, compared with cultured myotubes (Table 2). All 
myotubes in sections of human fetal muscle at 12 weeks gestation expressed developmental myosin strongly while 
fast myosin was expressed less strongly and more variably (Fig. 5A). Similarly, S21b nebulin (exon 144) was found 
in all fibres but with only a little variability. Staining fetal muscle of 12 weeks gestation for S21a nebulin (exon 143) 
gave a pattern similar to fast myosin staining; thus, many of the larger myotubes are less strongly-stained for both 
S21a and fast myosin than smaller myotubes (Fig. 5A). The larger ones may be primary myotubes and the smaller 
ones may be the secondary myotubes that appear a little later in human myogenesis.
By 17 weeks of fetal development, staining for S21a (exon 143) of the larger myotubes was stronger and the 
differences between 143 and 144 were less evident (Fig. 5B). Some very small myotubes expressing fast and fetal 
myosin are evident with mAb NEB-9H1 (exon 144) but not with mAb NEB-3F4 (exon 143) (Fig. 5B). These 
myotubes may be a subset of secondary myotubes sometimes referred to as tertiary myotubes16. From the results 
with these two fetal muscle samples, it seems that nebulin with exon 143 has appeared by 12 weeks gestation and 
may have increased further by 17 weeks.
Figure 2. Monoclonal antibodies against different nebulin epitopes recognize a protein of ca 800 kD on western 
blots. (A) Different mAb supernatants were applied to a strip blot of human muscle extract using a miniblotter. 
Lanes 1–7 and 9 are the eight mAbs in Table 1A that recognize exons 138–142. Lane 8 is a negative control and 
lane 10 is MANDYS1 mAb which recognizes 427 kD dystrophin. (B) In this case, the blot was cut into strips which 
were exposed to different mAb supernatants separately. The first lane is NEB-6B5 from lane 9 in (A) and lane 2 is 
MANDYS1 anti-dystrophin marker. NEB-9H1 is the exon 144 mAb and the two flanking lanes labelled “X” are 
two supernatants from the hybridoma fusion that were not specific for nebulin and not cloned; these are followed 
by two sub-clones each of the exon 143 mAbs, NEB-3F4 and NEB-6E6. (C) A freshly-made extract of human 
muscle was loaded into 3 lanes separated by pre-stained Mr markers. The blot was cut vertically into 3 sections 
through the Mr lanes and each section was developed with MANNES2A anti-nesprin-2 (792 kD), NEB-6B5 or 
MANDYS1 anti-dystrophin (427 kD), as described in Methods. The largest prestained Mr marker (250 kD) is 
also shown. The prestained marker images and the chemiluminescent images were exactly superimposed using 
the Photoshop “Apply Image” tool. In (B,C), the lanes were cut from the same blot, reassembled in sequence after 
development and exposed together to obtain chemiluminescent images; (A) is a single miniblotter blot.
Tissue Source
Relative expression
Ex143 Ex144
Myoblasts (5 days) <1 <1
Myotubes (5 days) 4.7 ± 0.4 (0.4%) 1160.7 ± 154.0
Myoblasts (25 years) <1 3.2 ± 0.9
Myotubes (25 years) 49.9 ± 3.7 (1.05%) 4721.1 ± 748.4
Myoblasts (53 years) <1 16.8 ± 2.8
Myotubes (53 years) 48.4 ± 9.3 (1.1%) 4310.3 ± 544.3
Fetal skeletal muscle 
(MRC Biobank) 904.8 ± 194.4 (16%) 4688.3 ± 652.8
Adult skeletal muscle 
(RJAH, 18 years) 32177.1 ± 2192.3 (72%) 12372.9 ± 3298.5
Table 2. Relative expression by qPCR of mRNAs for nebulin isoforms in human cultured cells and skeletal 
muscle. Three different immortalised myoblast lines were used and are identified by the age of the original 
muscle donor. Derivation of “relative expression” is described in Methods. The percentage exon 143 values in 
parenthesis are (ex143/[ex143 + ex144]) × 100. Values are mean ± SD of 3 determinations.
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The results suggest that the first nebulin produced during myogenesis contains only S21b (exon 144) 
super-repeat and that alternative splicing to produce additional nebulin molecules with the S21a (exon 143) 
super-repeat occurs at later stages of muscle differentiation and development.
In mature human quadriceps muscle, fibres expressing fast myosin usually express S21a nebu-
lin (exon 143). We tried to determine whether the variable expression of exon 143 between adjacent muscle 
fibres seen in Fig. 3 is related to any other property that shows this “fibre-typing” effect, the best known being 
the mixture, in various proportions, of fast-twitch and slow-twitch fibres of which most muscles are comprised. 
Serial sections of a human muscle were stained with mAbs against nebulin (143 or 144) or myosin (fast or slow). 
We did not attempt to distinguish between IIA and IIX fast myosin17. In Fig. 6, some of the fibres (40 out of 
Figure 3. Nebulin with S21b (exon 144) is found in cross-striations of all muscle fibres, but nebulin with S21a 
(exon 143) is found in some fibres only. Muscle sections (quadriceps) were labelled with either an exon 143 mAb 
(NEB-3F4) or the exon 144 mAb (NEB-9H1) and confocal images were acquired with either high magnification 
(63x objective: upper two frames) or at lower magnification (20x objective: lower two frames). For NEB-3F4, 
fibres are variably labelled strongly, weakly or not at all.
Biopsy 
Sample
No. of fibres 
counted
% fast 
fibres
% fast fibres 
exon 143+
% slow fibres 
exon 143+
Quads 1 62 63 92 29
Quads 2 110 55 98.4 41
Quads 3 100 53 84 10.6
Mean 93.3% 24.1%
95% CI 67.7–100% 6.3–64.5%
Table 3. The association between expression of fast myosin and nebulin exon 143 is significantly non-random. 
Logistical Regression Analysis (Logit Method) for a binary dependent variable was used to determine 95% 
confidence intervals (CI). The method gives the probability that association between fast myosin and nebulin 
exon 143 is random (50%).
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100 counted) are numbered to identify the same fibre in each of the serial sections. Two additional quadriceps 
biopsies from two different subjects were analysed in the same way and Table 3 shows the results from these 3 
experiments (the biopsy for Fig. 6 is “Quads 3” in Table 3). The great majority (93.3%) of fibres expressing fast 
myosin were stained by NEB-3F4 mAb (exon 143), but 24.1% of the fibres staining for slow myosin were also 
stained by NEB-3F4 mAb. Thus, fast fibres usually express S21a nebulin (exon 143) while slow fibres may express 
either S21a or S21b.
Even with this very small sample number (N = 3), the association between fast myosin and exon 143 expres-
sion was significant [p < 0.05] (Mean % of fast fibres that are exon 143+ = 93.3%; 95% CI range 66.7–100%), but 
no significant association between slow fibres and absence of exon 143 expression could be demonstrated at this 
probability level (Mean % of slow fibres that are exon 143+ = 24.1%; 95% CI range 6.3–64.5% [p > 0.05]).
Discussion
This study has proven, for the first time at the protein level, the existence of two alternatively-spliced nebulins, 
isoforms S21a with exon 143 and S21b with exon 144, previously known from mRNA studies only. Although 
each single nebulin mRNA contains either exon 143 or exon 144, and never both2, we have shown that all human 
multinucleate muscle fibres examined contain nebulin isoform S21b (exon 144) while some of them co-express 
nebulin S21a (exon 143). Because of the multinuclearity of the myofibres, it is not possible to say whether both 
Figure 4. Multinucleate human muscle myotubes in cell culture only produce the S21b (exon 144) isoform of 
nebulin and not the alternatively-spliced S21a isoform (exon 143). Two different immortalised cell lines were 
used, one derived from a 5-day old infant (left column) and one from a 53-year-old donor (right column). 
The exon 143 mAb shown is NEB-6E6 but identical results were obtained with NEB-3F4. The size bars are 25 
microns in each frame.
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alternative splicings occur within a single myofibre nucleus, or whether some myofibre nuclei express only exon 
143 and others only exon 144. The nebulin protein sequence encoded by exon 143 is highly-conserved across spe-
cies, suggesting that it may have a special function, such as specific interaction with another protein. For example, 
the binding site for KLHL40 is within S21, but its precise location is not known11. The existence in adult muscle 
of fibres containing only S21b (with exon 144) shows that the inferred special function of S21a is not required in 
all fibres. The expression of S21a in addition to S21b in some fibres may explain may explain why “fibre-typing” 
effects were observed in previous studies when sections were labelled with polyclonal pan-nebulin antibodies18.
Cultured myotubes in vitro contained only nebulin with exon 144 (Fig. 4), but by the second trimester of fetal 
development in vivo, most myotubes contained both nebulins (Fig. 5), suggesting developmental regulation of 
some kind. At 12 weeks gestation, the smaller fetal myotubes tended to be stained more strongly for both exon 
143 and fast myosin than the larger, primary, fetal myotubes (Fig. 5A). However, at 17 weeks gestation, some 
very small myotubes with fast myosin (possible tertiary myotubes16) were more strongly stained with the exon 
144 mAb (Fig. 5B). These observations, together with variation between individual adult fibres (Fig. 6), shows 
that expression of S21a (exon 143) is not the result of a simple or irreversible developmental switch. Splicing 
of primary RNA transcripts into mRNAs is determined by cis-acting sequences in adjacent introns and by 
trans-acting factors (proteins or micro-RNAs) which may themselves be regulated by epigenetic changes dur-
ing development. It remains to be determined whether the trans-acting factors affecting S21a expression are 
independently-regulated or linked to a specific gene-switching event during muscle development.
This first study at the protein level differs from earlier mRNA studies, since we are sampling only a small area 
of a human muscle section whereas mRNA was extracted from whole muscles. The latter gives a broader picture, 
but the former enables a direct appraisal of the role of fibre-types. Whereas mRNA studies showed that alterna-
tive splicing is not determined by the average fast/slow composition of muscle19, our ability to study splicing in 
individual fibres using antibodies has shown that it does depend to some extent on fibre-type, though it may not 
be directly-related to myosin isoform expression. The present human studies confirm and extend the work of 
Donner et al.19 on alternative splicing of mouse nebulin exons 127 and 128 (murine equivalent of human exons 
143 and 144) in different mouse muscles at different ages up to 6 weeks (near-adult in the mouse) by extracting 
RNA from whole mouse muscles. This mouse study found considerable differences between different muscles; 
thus, many muscles, including quadriceps and gastrocnemius, had mainly exon 128 by 6-weeks, though they 
expressed a lot of exon 127 at earlier stages, while some muscles (longus capitis) expressed almost exclusively 
exon 127 and others (diaphragm, masseter) expressed almost exclusively exon 128 at all ages. In human quadri-
ceps, most fast fibres expressed exon 143 and most slow fibres did not. It will be necessary to study other human 
muscles in order to determine whether alternative splicing varies with human muscle type, as it does between 
mouse muscles. Some other alternative splicings of human nebulin mRNA have been shown to occur only in 
soleus muscle, and not in other muscle types9, suggesting that post-transcriptional effects on nebulin expression 
may often be muscle-type-specific.
Future studies of biopsies from patients with neuromuscular disorders, including nemaline myopathy, and of a 
variety of muscles in addition to quadriceps, will be necessary to clarify the effects of muscle-type and disease state.
Materials and Methods
Ethical Approvals. The project was approved by the RJAH Hospital Research Committee. Animal proce-
dures for mouse monoclonal antibody production were carried out under UK Home Office Licence and approved 
by Keele University Animal Welfare and Ethical Review Body. All human tissue studies complied with the UK 
Human Tissue Act (2006). Use of donor muscle tissue from routine orthopaedic surgery with informed consent 
was approved by the UK NHS Review Body (NRES North West No 11/NW/0875). Other human muscle samples 
were obtained from the MRC Centre for Neuromuscular Disease Biobank, London. Parental or legal guardian 
informed consent was obtained for participants under the age of 16 years.
Production of recombinant immunogens. The DNA fragments containing nebulin exons 138–143 or 
138–144 were obtained from thigh muscle RNA by reverse transcription PCR, and cloned into pET32a-vector20. 
Plasmid constructs containing the correct insert were identified by Sanger sequencing. For screening, the cDNA 
fragments containing exon 143 or exon 144 alone, obtained from the pET32a construct by PCR, were cloned into 
pGEX4T-1 vector for expression as GST fusion proteins. All constructs were transformed into E. coli BL21 (DE3) 
and the expression was induced with IPTG (0.5 mM final concentration).
Production of monoclonal antibodies. Monoclonal antibody production was performed as previously 
described21. Spleen cells from hyper-immune BALB/c mice were fused with the Sp2/O mouse myeloma cell line 
using PEG1500 and plated in 960 wells of microtitre plates. After 10 days, the hybridomas were screened by 
ELISA, western blot and immunocytochemistry. Positive wells were cloned twice by limiting dilution.
Phage-displayed Random Peptide Library. Epitope mapping with a phage-displayed random 15-mer 
library was carried out according to a detailed protocol22. Briefly, antibody coated onto plastic dishes was used to 
select phage particles from a 15-mer peptide library in phage f88–4, maintained in the K91Kan strain of E. coli and 
generously supplied by G.P. Smith (University of Missouri). After 2–3 rounds of selection, individual phage-infected 
bacterial colonies positive for the antibody target on western blots were isolated and the expressed peptide sequence 
was identified by sequencing the phage DNA with a suitable primer (5′-AGTAGCAGAAGCCTGAAGA-3′).
Muscle cell culture. Clonal myoblast cell lines, immortalized by transduction with human telomerase 
reverse transcriptase (hTERT) and cyclin-dependent kinase-4 (Cdk4)23, were provided by Dr V. Mouly, Institut 
de Myologie, Paris. They were cultured in skeletal cell growth medium (Cat No: C-23060; PromoCell GmbH, 
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Heidelberg, Germany) containing supplement mix (Cat No: C-39365; PromoCell) with 20% Fetal Bovine Serum 
(Cat No: 10270; Gibco, ThermoFisher, Paisley, UK). Differentiation was induced at 80% confluency by washing 
the adherent myoblasts in medium lacking serum and then culturing in DMEM (Cat No: 31966-021; Gibco, 
ThermoFisher) supplemented with Insulin (1721 nM), Transferrin (68.7 nM), Selenium (38.7 nM) (ITS-X; Cat 
No: 51500-056; Gibco, ThermoFisher) and Penicillin-Streptomycin. After a further 4 days of cell culture, over 
60% of the cells had fused into myotubes.
Figure 5. Expression of nebulin protein S21a (with exon 143) increases progressively during human fetal 
muscle development, becoming as strong as S21b (exon 144) in some fibres by 17-weeks of gestation. Frozen 
sections of (A) 12-week or (B) 17-week gestation fetal muscle were stained with mAbs against S21a (NEB-3F4 
or “NEB143”), S21b (NEB-9H1 or “NEB144”) or fast, fetal and developmental myosin isoforms as indicated. 
Myosin stainings were counter-stained for nuclei with haematoxylin. Note the central nuclei in fetal myotubes. 
Surrounding connective tissue, revealed by haematoxylin-stained nuclei, is not stained by any of the mAbs. The 
50 micron size bar in the first frame applies to all 8 frames.
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Immunolabelling of muscle sections using peroxidise. Immunolabelling was performed on unfixed 
5–6 micron thick sections of muscle frozen in isopentane cooled in liquid nitrogen. Sections were immunola-
belled with nebulin primary antibodies (diluted 1:3 in PBS buffer) for 1 hour and visualised using the X-cell Plus 
Polymer kit (A.Menarini Diagnostics, Winnersh-Wokingham, UK) followed by 3, 3′ diaminobenzidine and per-
oxidase. Counterstaining was with haematoxylin. After labelling and counterstaining, sections were dehydrated, 
Figure 6. Fibres in human quadriceps muscle expressing the fast myosin isoform are usually also stained by the 
mAbs specific for the S21a isoform (NEB-3F4). Serial sections from a quadriceps sample were immunostained 
by the peroxidase method with mAbs against nebulin encoded by exon 143, fast myosin or slow myosin (see 
Methods). Some of the fibres are numbered to enable easier comparison of the three serial sections. Most fibres 
are either “fast” or “slow” but some “hybrid” fibres also occur (e.g. 17 and 40). Most fibres with fast myosin are 
also labelled with NEB-3F4. The 200 micron size bar in the bottom frame applies to all 3 frames.
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cleared in xylene and mounted in DPX. Monoclonal antibodies (mAbs) against myosin heavy-chains from Leica 
Biosystems were: Fast myosin (NCL-MHCf), Slow myosin (NCL-MHCs), Neonatal myosin (NCL-MHCn) and 
Developmental myosin (NCL-MHCd). They were used according to supplier’s recommendations and labelled 
with the Menarini kit described above. The muscle biopsies (quadriceps) were from a 15-year old male cerebral 
palsy patient, the MRC Biobank or a mild myopathy patient (13 year old female).
Immunofluorescence microscopy. Immunolabelling was performed on cells cultured on coverslips, 
fixed with 50:50 acetone-methanol and washed with PBS, or on muscle frozen sections. Monoclonal antibodies 
in culture supernatants were diluted 1:3 in PBS and incubated on the specimen for 1 hour. Following washing, 
incubation was continued with 5 µg/ml goat anti-mouse ALEXA 488 (Molecular Probes, Eugene, Oregon, USA) 
secondary antibody diluted in PBS containing 1% horse serum, 1% fetal bovine serum and 0.1% BSA, for 1 hour. 
DAPI (diamidinophenylindole at 200 ng/ml) was added for the final 10 minutes of incubation to counterstain 
nuclei before mounting in Hydromount (Merck). Sequential confocal scans performed with a Leica TCS SP5 
spectral confocal microscope (Leica Microsystems, Milton Keynes, UK).
SDS-polyacrylamide gel electrophoresis and Western blotting. Human muscle tissue was extracted 
in: 50 mM Tris pH 6.8, 1% EDTA, 10% SDS, 5% beta-mercaptoethanol, 10% glycerol with protease inhibitors. 
After the addition of bromophenol blue and after boiling, the extract was loaded, either as a single strip or in 
formed wells, and subjected to SDS-PAGE using 4 to 12% polyacrylamide gradient gels and transferred to 
nitrocellulose membranes (Protan BA85, Whatman). After blocking non-specific sites with 5% skimmed milk 
protein, membranes were incubated for 1 hour with monoclonal antibody (1/50), followed by washing and incu-
bation for 1 hour with peroxidase-labelled rabbit anti-mouse immunoglobulins (1/1000, Dakopatts, Denmark). 
Antibody reacting bands were visualized with West Pico or West Femto chemiluminescent detection systems 
(Pierce, Thermofisher). Prestained Mr markers were EZ-Run 10–170 kD or PageRuler Plus 10–250 kD (both 
Thermofisher).
qPCR. Total RNA was prepared from cultured cells and from skeletal muscle samples using RNeasy Plus Mini 
Kit (Qiagen) and quantified with a NanoDrop ND-1000 spectrophotometer. Fetal muscle was obtained from the 
MRC Centre for Neuromuscular Disease Biobank, London. Adult muscle (18 year male) was obtained during rou-
tine surgery at RJAH Orthopaedic Hospital, Oswestry (with informed consent and ethical approval). Total RNA 
(maximum of 2.5 µg in a 20 µL reaction) was reverse transcribed (SuperScript VILO cDNA Synthesis Kit; Applied 
Biosystems) and then diluted with sterile water, in order to achieve the cDNA equivalent of 10 ng total RNA for 
each 20 µL reaction in the qPCR plate. Primers were: Ex143F: 5′GCTGATTATGAGCAGCGGAAAG or Ex144F: 
5′GGATGTAATGAAATTCTGCGT in combination with Ex145R: 5′TCGCTGATTTGTTTGTTGACTT.
Relative quantitative PCR was performed using SYBR green detection in an ABI 7500 Real Time PCR sys-
tem (Applied Biosystems). Reaction wells contained 10 µL SYBR Select Master Mix (Applied Biosystems), 1.5 µL 
cDNA, 300 nM Forward and 300 nM Reverse primers in a final volume of 20 µL. For each preparation of cDNA, 
each target sequence was amplified along with two endogenous controls (Beta-actin and GAPDH). Quantitation 
of target transcripts relative to the two endogenous reference transcripts were calculated by the 2−∆CT method24,25. 
The efficiency of primer pairs for quantitative PCR was determined by making serial dilutions of the cDNA, 
performing absolute quantitation, plotting CT versus log cDNA dilution, with the slope of the line being used to 
calculate efficiency25. Dissociation curves were obtained to ensure that each primer pair gave a single peak.
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